Latanoprost/Timolol Polpharma

Latanoprost, the active ingredient in Latanoprost/Timolol Polpharma, is a prostaglandin analog / beta‑blocker presented as an ophthalmic solution (eye drops) for ocular use. It is indicated for the management of open‑angle glaucoma and ocular hypertension in adult patients.

GNH USA supplies Latanoprost/Timolol Polpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across global markets. The company adheres to stringent manufacturing standards and provides reliable logistics for timely delivery.

Latanoprost/Timolol is used in ophthalmology to lower intra‑ocular pressure by targeting the prostaglandin and beta‑adrenergic pathways.

Open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression. Ocular hypertension: lowers eye pressure to prevent conversion to glaucoma. Secondary open‑angle glaucoma: provides additional pressure‑lowering effect when monotherapy is insufficient.

The following adverse reactions have been reported with the combination of latanoprost and timolol.

Common Side Effects: - Eye irritation or burning sensation. - Transient blurred vision after instillation. - Conjunctival hyperemia (redness). - Increased eyelash growth. - Darkening of the iris or peri‑ocular skin. - Dry eye sensation.

Serious or Rare Side Effects: - Severe allergic reaction (e.g., angio‑edema, anaphylaxis). - Sudden loss of vision or acute ocular pain. - Systemic bradycardia or hypotension. - Respiratory distress in patients with asthma or COPD. - Persistent corneal edema. - Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before using Latanoprost/Timolol, consider the following safety measures.

Assess respiratory status: avoid in patients with uncontrolled asthma or severe COPD. Cardiovascular evaluation: contraindicated in bradycardia, heart block, or decompensated heart failure. Pregnancy and lactation: use only if the potential benefit justifies the potential risk. Monitor intra‑ocular pressure: regular eye‑pressure checks are required to assess efficacy. Avoid concurrent beta‑blocker eye drops: may increase systemic absorption. Store at room temperature: keep the bottle in the original packaging, protect from light and moisture.

Latanoprost/Timolol may interact with other medicines; monitor patients accordingly.

Major Interactions (Avoid): - Asthma or severe COPD medications: additive bronchoconstriction risk. - Systemic beta‑blockers: may cause excessive bradycardia or hypotension. - Calcium channel blockers: can enhance timolol‑induced cardiac effects.

Moderate Interactions (Monitor Closely): - Other intra‑ocular pressure‑lowering agents (e.g., carbonic anhydrase inhibitors): may increase ocular hypotension. - Anticholinergic eye drops: could affect pupil size and comfort. - Non‑steroidal anti‑inflammatory drugs (topical): may alter prostaglandin metabolism.